News | Cardiac Resynchronization Therapy Devices (CRT) | May 13, 2020

Left Bundle Branch Pacing is Feasible as a Novel Strategy For Cardiac Resynchronization Therapy

Results from the International LBBP Collaborative Study Group provides remarkably low and stable pacing thresholds for CRT

Left bundle branch (LBBP) activation imaging shown using wall motion color codes on echo imaging from Canon. #HRS2020 #heartrhythm2020

Left bundle branch (LBBP) activation imaging shown using wall motion color codes on dyamic echo imaging from Canon. 


May 13, 2020 — Cardiac resynchronization therapy (CRT) using biventricular pacing (BVP) or His bundle pacing (HBP) is effective in patients with heart failure (HF), bundle branch block or RV pacing. Intraseptal left bundle branch pacing (LBBP) has been reported as an alternative option for CRT and the aim of this late-breaking trial presented at the Heart Rhythm Society (HRS) 2020 Science virtual meeting was to assess the feasibility and outcomes of LBBP in CRT candidates in an international, multicenter, collaborative study.

The study found LBBP is feasible, safe and provides an alternative option for cardiac resynchronization therapy. Researchers said the LBBP provides remarkably low and stable pacing thresholds. Insights from this study may provide better electrophysiologic understanding of LBBP and its role in CRT. The study was presented by Pugazhendhi Vijayaraman, M.D., FHRS, Geisinger Heart Institute, Mountain Top, Penn. 

In the study, LBBP was attempted in patients with LVEF<50% and indications for CRT/pacing at eight international centers. Indications, procedural and pacing parameters, NYHA class, HF hospitalization, echocardiographic data and lead complications were assessed. LBBP was performed as a rescue or primary approach to achieve CRT utilizing SelectSecure 3830 pacing lead. LBB capture was assessed by the presence of: LBB potentials, paced RBBB morphology, nonselective (NS) to selective (S) or myocardial capture, peak LV activation time (pLVAT)<90ms in V6, response to programmed stimulation.

LBBP was attempted in 325 patients and CRT was successfully achieved in 277 (85%); failure due to incomplete CRT 27, failed deep septal deployment 21. Age 71±13 yrs, female 37%, HTN 68%, DM 38%, CAD 47%. Ischemic CMP 36%, nonischemic CMP 59%; LVEF <35% in 65% pts. QRS morphology at baseline: LBBB 42%, RBBB 18%, IVCD 12%, RVP 13%, narrow 16%. Procedure and fluoroscopy duration were 105±54 and 19±16 min. LBBP threshold and R-wave amplitudes were 0.76±[email protected] and 11.5±6.8mV at implant and remained stable during mean f/u of 6±5 months. LBBP resulted in significant narrowing of QRS from 156±32ms to 137±22ms (p<0.0001) with pLVAT of 83±16ms. EF improved from 32±9 to 44±11% (p<0.0001). LBB capture evidence, echo and clinical outcomes and complications will be presented.

The researchers said randomized, controlled trials comparing conduction system pacing to BVP will be necessary to show further proof of concept.

Find links to all the Heart Rhythm Society 2020 Late-Breaking Clinical Trials in Electrophysiology

Related Content

News | Cardiac Resynchronization Therapy Devices (CRT)

October 27, 2021 ​​— EBR Systems Inc., developer of the world’s first wireless cardiac pacing system for heart failure ...

Home October 27, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

August 3, 2021 — In association with Heart Rhythm 2021, Biotronik announced first enrollments in the landmark BIO ...

Home August 03, 2021
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

March 3, 2021 — Medtronic announced new results from the landmark REVERSE trial, evaluating outcomes of cardiac ...

Home March 03, 2021
Home
Feature | Cardiac Resynchronization Therapy Devices (CRT) | Valentina Kutyifa M.D., Ph.D.

Cardiovascular disease is the leading cause of death for women in North America, and women with heart failure often ...

Home March 09, 2020
Home
News | Cardiac Resynchronization Therapy Devices (CRT) | Dave Fornell, Editor

May 15, 2019 — A pilot trial has shown His pacing in cardiac resynchronization therapy (CRT) has been shown to ...

Home May 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 29, 2019 — Biotronik announced the full commercial launch of the Acticor device family, including Acticor DX and ...

Home April 29, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

April 18, 2019 – Biotronik announced the European market release of what it calls the world’s smallest implantable ...

Home April 18, 2019
Home
Technology | Cardiac Resynchronization Therapy Devices (CRT)

March 15, 2019 – Biotronik announced U.S. Food and Drug Administration (FDA) approval of the Acticor and Rivacor high ...

Home March 15, 2019
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

May 22, 2018 — Medtronic plc announced study results showing its AdaptivCRT algorithm is associated with improved ...

Home May 22, 2018
Home
News | Cardiac Resynchronization Therapy Devices (CRT)

February 26, 2018 — The U.S. Food and Drug Administration (FDA) announced that Medtronic is recalling certain ...

Home February 26, 2018
Home
Subscribe Now